Loading organizations...
Exsilio Therapeutics, recently rebranded as Averna Therapeutics, is a Boston-based biotechnology company developing genomic medicines that use mRNA encoded in lipid nanoparticles to insert entire therapeutic genes into cells. The preclinical platform combines in silico modeling and wet lab research to create programmable genetic elements capable of redosing for genetic diseases, cancer, and autoimmune conditions. In June 2024, the company emerged from stealth by securing $82 million in Series A funding to advance its pipeline of whole-gene delivery therapies. This financing round was co-led by Novartis Venture Fund and Delos Capital, with participation from institutional investors including OrbiMed, Insight Partners, and CRISPR Therapeutics. The organization recently appointed Thomas M. Barnes as chief executive officer, while former interim leader Tal Zaks transitioned to executive chairman. Exsilio Therapeutics was founded in 2022 by Roy Amariglio and Erez Levanon.
Exsilio Therapeutics has raised $82.0M across 1 funding round.
Exsilio Therapeutics has raised $82.0M in total across 1 funding round.
Exsilio Therapeutics has raised $82.0M in total across 1 funding round.
Exsilio Therapeutics's investors include Delos Capital, Novartis Venture Fund.
Exsilio Therapeutics has raised $82.0M across 1 funding round. Most recently, it raised $82.0M Series A in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2024 | $82M Series A | Delos Capital | Novartis Venture Fund | Announced |
Exsilio Therapeutics, now operating as Averna Therapeutics, is a biotechnology company developing genomic medicines that use mRNA encoded in lipid nanoparticles (LNPs) to precisely insert therapeutic genes into safe harbor sites in cells, enabling durable treatment for genetic diseases, cancer, and autoimmune conditions.[1][2][3][7] The platform leverages naturally occurring genetic elements, predictive in silico modeling, and wet lab experimentation for safe, scalable, redosable therapies that overcome limitations of viral vectors and traditional gene editing by allowing repeated dosing without immune interference.[2][3][7] Launched from stealth in June 2024 with $82 million in Series A financing, the company targets broad disease applications with curative potential, progressing toward lead candidate selection.[2][3]
This approach serves patients with hard-to-treat conditions by providing permanent gene integration via non-viral delivery, solving problems like transient effects, delivery challenges, and single-dose constraints in existing genomic medicines.[1][3][5] Early momentum includes strong investor backing from Novartis Venture Fund, Delos Capital, OrbiMed, and others, plus leadership from biotech veterans, positioning it for rapid platform advancement.[2][4]
Exsilio Therapeutics emerged from stealth on June 25, 2024, seed-funded by OrbiMed and raising $82 million in Series A co-led by Novartis Venture Fund and Delos Capital, with participation from Insight Partners, CRISPR Therapeutics, and others.[2][4][5] The company was founded by an interdisciplinary team bridging computational and experimental biology, inspired by naturally occurring genetic elements and mRNA successes like Moderna's COVID-19 vaccine.[3][5] Key leadership includes Tal Zaks, former Moderna Chief Medical Officer, serving as chairman and interim CEO, bringing expertise in mRNA therapeutics to extend their payload for permanent gene insertion.[3][4][5]
The idea stemmed from addressing gene therapy shortcomings—such as immune responses limiting redosing and viral delivery inefficiencies—by encoding programmable elements in mRNA for LNP delivery.[2][3][5] Pivotal early traction came from building a platform combining in silico prediction with lab validation, debuting amid FDA guidance on platform technologies and recent approvals like CRISPR therapies.[5] By 2025, it rebranded to Averna Therapeutics, signaling evolution while retaining its core mission.[6][7]
Exsilio (now Averna) rides the genomic medicine surge, fueled by mRNA breakthroughs (e.g., Nobel-winning LNP tech) and approvals like LUXTURNA (2017) and CRISPR therapies, addressing scalability gaps in gene editing.[5] Timing aligns with FDA draft guidance on platform technologies, accelerating regulatory paths for modular, non-viral approaches amid rising demand for curative therapies beyond rare diseases.[5] Market forces favoring it include proven LNP manufacturing from COVID vaccines, cost-effective scaling, and investor enthusiasm for redosable options tackling $100B+ markets in genetics, oncology, and immunology.[2][3]
It influences the ecosystem by pioneering "software-like" mRNA genomic tools, potentially standardizing safe harbor insertions and expanding access via repeat dosing, bridging transient mRNA therapies with permanent gene edits.[3][5][7]
Averna Therapeutics is poised to nominate lead candidates soon, leveraging its $82M war chest for preclinical advancement into genetic diseases and beyond, with human trials likely in 2026-2027.[2][3][7] Trends like AI-driven in silico design, LNP optimizations, and combo therapies will accelerate its platform, while partnerships (hinted by blue-chip backers like CRISPR Therapeutics) could fast-track applications.[2][5] Its influence may evolve from platform innovator to category leader in redosable genomic meds, redefining curative potential—if safety data holds in clinic—ultimately leaping gene therapy forward as promised by its original "Exsilio" name.[3][7]
